Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Inv. presentation
Quarterly results
Director comp.
Appointed director
|
|
23andMe Holding Co.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/08/2023 |
8-K
| Quarterly results |
| 05/25/2023 |
8-K
| Quarterly results|
Docs:
|
"23andMe Reports FY2023 Fourth Quarter and Full Year Financial Results Achieved FY2023 financial guidance FY2023 full year revenue grew 10% over prior year Webcast today, May 25, 2023 at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif., May 25, 2023 -- 23andMe Holding Co. , a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, today reported its financial results for the fourth quarter and full year of fiscal year 2023 , which ended March 31, 2023. 23andMe is the only company with multiple U.S. Food and Drug Administration authorizations for over-the-counter genetic health risk reports. The Company has also created the world’s largest, re-contactable crowdsourced platform of genotypic information paired ..." |
|
| 11/07/2022 |
8-K
| Quarterly results|
Docs:
|
"23andMe Reports FY2023 Second Quarter Financial Results Second quarter revenue grew 37% to $76 million Consumer revenue grew 27% year over year due to the addition of telehealth revenue On track to achieve FY2023 financial guidance South San Francisco, Calif., November 7, 2022 -- 23andMe Holding Co. , a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, today reported its financial results for the second quarter of its fiscal year 2023 , which ended September 30, 2022. 23andMe is the only company with multiple FDA authorizations for over-the-counter genetic health risk reports, and in particular the only company the FDA has authorized to provide, without physician involvement, genetic cancer risk reports..." |
|
| 08/08/2022 |
8-K
| Quarterly results |
| 05/26/2022 |
8-K
| Quarterly results |
| 02/10/2022 |
8-K
| Quarterly results|
Docs:
|
"23andMe Reports FY2022 Third Quarter Financial Results Third quarter revenue of $57 million Therapeutics group advances first wholly-owned immuno-oncology antibody into clinical trials Vision of genetics-based primary care offers potential for millions of people to live healthier lives SUNNYVALE, Calif., February 10, 2022 -- 23andMe Holding Co. , a leading consumer genetics and research company with a mission to help people access, understand, and benefit from the human genome, today reported its financial results for the third quarter of its fiscal year 2022 , which ended December 31, 2021. 23andMe is the only company with multiple FDA authorizations for over-the-counter genetic health risk reports, and in particular the only company FDA authorized to provide, without physician involvemen..." |
|
| 11/10/2021 |
8-K
| Quarterly results |
| 08/13/2021 |
8-K
| Quarterly results |
|
|